Avoro Capital Advisors Reduces $17M in Tango Therapeutics, Inc. ($TNGX)

Avoro Capital Advisors has exited its position in Tango Therapeutics, Inc. (NasdaqGM: TNGX), completely selling off its 545,000 shares. This move was detailed in the firm's latest Form 13F filing with the SEC, covering the quarter ended December 31, 2025.

What Changed in Avoro Capital Advisors' Tango Therapeutics Position

Avoro Capital Advisors sold all of its 545,000 shares in Tango Therapeutics, resulting in a 100% decrease in its holdings. The firm no longer holds any shares in the company as of the end of the reporting period.

Other Institutional Activity in Tango Therapeutics

RTW Investments, LP significantly boosted its holdings in Tango Therapeutics, adding 11,809,392 shares to end with 13,300,620 shares valued at about $278.2 million. Similarly, FMR LLC increased its position by 7,038,371 shares, reaching a total of 9,905,919 shares worth approximately $207.2 million. Adage Capital Partners GP, L.L.C. also grew its stake by 2,201,561 shares, ending with 12,809,485 shares valued at $267.9 million. Meanwhile, TCG Crossover Management, LLC and Farallon Capital Management LLC reduced their holdings by 2,231,023 and 3,964,000 shares, respectively.

Tango Therapeutics Stock Snapshot

Shares of Tango Therapeutics traded at $29.81 as of the latest update. The company, with a market capitalization of around $5.04 billion, operates in the biotechnology industry. It has a forward P/E ratio of -19.74, suggesting it's not currently profitable. The stock's 52-week range is between $4.40 and $32.79, with a 50-day moving average of $23.50 and a 200-day moving average of $13.85. Tango Therapeutics shows strong liquidity with a current ratio of 27.38 and a quick ratio of 26.51, alongside a debt-to-equity ratio of 8.38.

Recent Earnings

Tango Therapeutics reported revenue of $56.99 million. However, the company posted a net margin of -188.15% and a return on equity of -38.42%, indicating financial challenges. Investors can look forward to the next earnings report on May 13, 2026.

Insider Buying and Selling at Tango Therapeutics, Inc.

Several insiders have been active in Tango Therapeutics. On June 5, 2026, Mace Rothenberg bought 4,000 shares, while Sung Lee purchased 570 shares. Lesley Ann Calhoun and John Ketchum each acquired 25,000 shares. These transactions were not part of a pre-arranged trading plan.

Analysts Set New Price Targets

Analysts have recently updated their outlooks on Tango Therapeutics. On June 11, 2026, Canaccord Genuity maintained a 'buy' rating with a $42.00 price target. HC Wainwright & Co. also maintained a 'buy' rating with a $66.00 target on June 9, 2026. Meanwhile, Piper Sandler downgraded the stock to 'hold' with a $24.00 target on May 15, 2026. The consensus among analysts is a 'strong buy' with an average target price of $40.45.

About Tango Therapeutics

Tango Therapeutics, Inc. is a biotechnology company based in Boston, Massachusetts, focused on precision oncology. Founded in 2017, the company develops targeted therapies for cancer patients with unmet medical needs. Its pipeline includes PRMT5 inhibitors like TNG462 and TNG456 for treating various cancers, and TNG260, aimed at reversing immune evasion in certain lung cancer mutations. The company is led by CEO Dr. Malte Peters and employs 137 people.

Bottom Line

Avoro Capital Advisors' complete exit from Tango Therapeutics highlights the shifting dynamics among institutional investors. While Avoro sold its entire stake, other major funds have increased their positions, showing varied confidence levels in the company's future. As always, keep in mind that 13F filings reflect past positions and may not indicate current holdings.